Rituximab Administration and Reactivation of HBV
Hepatitis Research and Treatment · 2010
DOI: 10.1155/2010/182067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von Yutaka Tsutsumi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Rituximab is a drug used for the treatment of B-cell non-Hodgkin's lymphoma, and its range of use has expanded to the treatment of collagen diseases such as idiopathic thrombocytopenic purpura and rheumatoid arthritis. One serious complication of rituximab use is the reactivation of dormant hepatitis B virus, and prevention of this phenomenon has become an urgent issue. This paper provides a general outline of the problem through an analysis of patient cases that we and other groups have experienced to date.
Autor:innen und Institutionen
- Department of Hematology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan.
Zitieren
APA
Tsutsumi, Y., Ogasawara, R., Kamihara, Y., Ito, S., Yamamoto, Y., Tanaka, J., Asaka, M., & Imamura, M. (2010). Rituximab Administration and Reactivation of HBV. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/182067
Vancouver
Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, et al. Rituximab Administration and Reactivation of HBV. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/182067
BibTeX
@article{Tsutsumi2010,
author = {Tsutsumi, Yutaka and Ogasawara, Reiki and Kamihara, Yusuke and Ito, Shinichi and Yamamoto, Yoshiya and Tanaka, Junji and Asaka, Masahiro and Imamura, Masahiro},
title = {Rituximab Administration and Reactivation of HBV},
journal = {Hepatitis Research and Treatment},
year = {2010},
doi = {10.1155/2010/182067}
}
EUVIMED